Top 25 Spotlight – Radiant Fluidics

Automating the Next Era of Cancer Care

In oncology, radiopharmaceuticals—targeted therapeutics that deliver localized radiation directly to cancer cells—represent one of the most promising frontiers in modern medicine. However, bringing these life-saving drugs from a research lab to a patient’s bedside requires navigating a delicate and high-risk bottleneck between development and clinical-scale production.

Developing radiopharmaceuticals is a painstaking, highly manual process. Radiochemists perform delicate chemistry steps on radioactive materials. Because procedures are largely done by hand, progress is slow, difficult to replicate, and exposes specialized researchers to radiation with every procedure.

Compounding this operational friction is a systemic tooling problem: every time a novel radiopharmaceutical program matures, researchers are forced to rebuild their processes from scratch. This reset creates months of friction and costly delays at the exact moment a promising therapeutic is racing toward clinical trials.

The demand for better development infrastructure comes as the global radiopharmaceutical market hits a massive inflection point. Driven by blockbuster approvals like Novartis’s targeted radioligand therapies Pluvicto and Lutathera—which together generated nearly $3 billion in 2025 annual sales. Pluvicto was recently approved for use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer, nearly tripling its eligible patient population and signaling a broader shift in how clinicians are sequencing cancer treatment. Pharmaceutical giants are betting heavily on radiopharmaceuticals, with over $13B in acquisitions and licensing deals in under a year, drawn by a pipeline across an expanding range of cancer types.

Yet, while capital pours into discovering new radiopharmaceuticals, laboratory tooling has remained stuck in the past. Automated tools that replace manual chemistry remove a dangerous physical burden from researchers while accelerating the delivery of targeted cancer treatments to waiting patients.

And that’s where Radiant Fluidics enters the picture. 

The Plug-and-Play Precision Platform

What They’ve Done: Radiant Fluidics engineered TACU to solve radiochemistry’s early-stage development bottleneck. Operating much like a high-precision printer, TACU runs on interchangeable, pre-sealed cartridges tailored to specific chemical processes. Researchers simply load the cartridge, and TACU automatically executes the process while logging all operational data in real time.

TACU is purpose-built for early-stage discovery—the exact phase when scientists are still refining how a drug should be made. Because the same platform and workflow carry forward as a program advances toward clinical production, research labs skip the months of rebuilding that normally follows once a process is finalized.

TACU has already achieved technical validation at world-leading research institutions. After operating its first unit, one partner site independently requested two additional systems to support an early-phase clinical trial.

Why NVBC: Advancing through the 2026 New Ventures BC Competition, presented by Innovate BC, allows the leadership team to crystallize their commercial strategy alongside top provincial mentors and investors. The competition also provides a unique platform for the Radiant team to showcase how local, engineered hardware can solve global constraints in nuclear medicine.

Up Next: Radiant Fluidics is raising capital to build out its team and expand its growing installed base across leading research institutes and commercial development labs.

Accelerating Life-Saving Therapies

The pipeline for new cancer treatments often moves too slowly for the patients waiting on the other end. While major pharmaceutical companies race to discover novel radiopharmaceuticals, Radiant Fluidics provides the missing operational bridge needed to move those discoveries out of the laboratory and into human clinical trials faster.

Beyond TACU’s early commercial traction, the company’s executives and directors bring a track record of building and scaling radiopharmaceutical and lab automation companies to high-value acquisitions by global industry leaders.

With a heavily de-risked platform, organic customer demand, and a team that has executed this exact playbook before, Radiant Fluidics offers investors and research partners immediate operational value at the leading edge of nuclear medicine.